The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer
Authors:
- 1 October 2019
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 5 (10) , 1510-1511
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal CancerJAMA Oncology, 2019
- HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal CancerThe Oncologist, 2019
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialThe Lancet Oncology, 2016
- The genomic landscape of response to EGFR blockade in colorectal cancerNature, 2015
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patientsBritish Journal of Cancer, 2013